Advancing Precision Medicine in Oncology through Strategic Partnerships

Transforming Cancer Diagnostics and Therapeutics with A*STAR and STCC

In collaboration with the Singapore Translational Cancer Consortium (STCC) and Roche, A*STAR is building a comprehensive framework for precision oncology in Singapore. This initiative aims to enhance patient access to targeted genomic profiling and therapeutic options, leveraging real-world data and a national clinico-genomic cancer database. With cutting-edge developments from A*STAR spinoffs like MiRXES, Lucence, and Lion TCR, the project is accelerating the clinical adoption of precision oncology, improving treatment outcomes, and paving the way for personalised cancer care.

The objectives

Building a Robust Real-World Data Infrastructure for Precision Oncology

This initiative aims to establish a national clinico-genomic cancer database in Singapore, providing real-world data to support precision oncology. By building this infrastructure, A*STAR, in collaboration with STCC and Roche, seeks to generate valuable insights into cancer trends and treatment outcomes, enabling more effective and targeted interventions.

Enhancing Access to Genomic Profiling and Personalised Treatments

The project’s goal is to expand patient access to genomic profiling and molecularly-guided therapies. By offering advanced diagnostic tools and personalised treatment options, the initiative aims to improve patient outcomes, particularly for complex and hard-to-treat cancers. This aligns with the broader mission to deliver precision medicine in oncology.

Accelerating Clinical Adoption of Precision Oncology Models

A key objective is to drive the clinical adoption of precision oncology care models across Singapore. By integrating innovations from A*STAR spinoffs like MiRXES, Lucence, and Lion TCR, the project supports early detection, personalised diagnostics, and novel therapies. This collaborative approach aims to standardise and enhance precision cancer care within the healthcare system.

The impact

This precision oncology initiative has significantly improved early cancer detection and personalised treatment options. By leveraging A*STAR spinoffs like MiRXES, innovative diagnostics using miRNA are now available for early detection of gastric cancer, allowing clinicians to tailor treatments based on individual patient profiles and support more effective interventions. Additionally, the initiative has expanded genomic profiling capabilities for various cancers, thanks to contributions from Lucence. This enables precise detection of actionable mutations across a range of solid tumours and haematological malignancies, leading to targeted therapies that align with each patient’s unique cancer profile.

Furthermore, Lion TCR has made strides in developing novel immunotherapies, particularly for Hepatitis B-associated liver cancer. This focus on virus-related cancers represents a breakthrough in the field of immunotherapy, offering new hope to patients with limited treatment options and showcasing A*STAR's pioneering role in cancer treatment. Beyond these advancements, the project has established a national clinico-genomic cancer database, laying a strong foundation for Singapore’s future in precision oncology. By integrating real-world data into clinical research, the initiative accelerates the clinical adoption of precision oncology models, creating a sustainable ecosystem that enhances cancer care and research nationwide.